Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of Carboplatin, Paclitaxel and Bevacizumab as First Line Chemotherapy and Consolidation for Advanced Ovarian Cancer

NCT00129727 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00129727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00129727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of Carboplatin, Paclitaxel and Bevacizumab as First Line Chemotherapy and Consolidation for Advanced Ovarian Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
February 28, 2009
Enrollment
62 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer